Skip to content
Screener

Pacira BioSciences, Inc. PCRX Q2 2026 earnings

Reported August 4, 2026 · After market close

Revenue$192.4MBeat by $1.3M
EPS$0.73Beat by $0.08
Revenue estimate$191.1M
EPS estimate$0.65
“The first half of 2026 was marked by solid revenue growth and strong execution of our 5x30 strategy across the business. Just 18 months into the initiative, we are delivering meaningful progress against each of our strategic objectives to drive long-term growth and create significant value. The quarter was also highlighted by our recently closed transaction with Zimmer Biomet, which positions iovera®° to reach its full global potential while preserving Pacira's participation in its future success and further sharpening our focus as an innovation-driven biopharmaceutical company.”
Frank D. Lee

Next report

Nov 5, 2026 (In 3 days)
Revenue estimate$182.9M
EPS estimate$0.73

Financials

Q2 2026

Income statement

See full
Revenue$192.4M+6.2%
Gross profit$148.2M+5.7%
Operating income$4.3M-49.8%
Net income$4.7M+196%
EPS (diluted)$0.12+209%

Balance sheet

See full
Cash & equivalents$205.9M-31.5%
Total debt$412.1M+17.4%
Total equity$672.0M-11.3%
Total assets$1.2B-19.1%

Cash flow

See full
Operating cash flow$57.5M+378%
CapEx$1.3M-50.5%
Free cash flow$56.1M+503%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$1.45B+52.0%
Enterprise value$1.66B+34.5%
P/E99.2×—
P/S2×+0.6×

Profitability

See full
Gross margin79.2%+1.0pp
Operating margin2.7%—
Net margin2%—
FCF margin24.1%+7.5pp

Returns & leverage

See full
Return on equity2%—
Debt / equity0.6×+0.1×
Current ratio5×+2.7×

Segments

By product

See full
EXPAREL$147.8M+3.4%
ZILRETTA$32.6M+4.2%
iovera°$6.8M+21.8%
Bupivacaine liposome injectable suspension$3.2M+533%

By segment

See full
Reportable Segment$192.4M+6.2%

FAQ

When did Pacira BioSciences, Inc. report Q2 2026 earnings?
Pacira BioSciences, Inc. (PCRX) reported Q2 2026 earnings on August 4, 2026 after market close.
What were Pacira BioSciences, Inc.'s Q2 2026 revenue and EPS?
Pacira BioSciences, Inc. reported revenue of $192.4M and eps of $0.73 for Q2 2026.
Did Pacira BioSciences, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $191.1M by $1.3M. EPS beat the consensus estimate of $0.65 by $0.08.
How did Pacira BioSciences, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 6.2% from $181.1M a year earlier and eps declined 1.4% from $0.74.
Where can I find Pacira BioSciences, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-052527) and the 10-Q periodic report (0001628280-26-052635) directly on SEC EDGAR. The filing index links above go to sec.gov.